Skip to main content
Premium Trial:

Request an Annual Quote

Roche Discloses Potential $625M Price Tag for Ariosa

NEW YORK (GenomeWeb) – Roche disclosed this week that it is paying up to $625 million for non-invasive prenatal testing firm Ariosa Diagnostics.

The terms of the deal include a cash payment of $400 million and up to $225 million from a contingent consideration arrangement, Roche said in its financial report. It also disclosed that it is paying up to $121 million for informatics company Bina Technologies, which it acquired in December.

On Wednesday, Roche reported a 3 percent increase year over year in its full-year 2014 diagnostic revenues, including a 6 percent increase in its molecular diagnostics revenues. The company did not break out its next-generation sequencing sales, but said that excluding those sales, the MDx business was up 8 percent year over year in 2014.